Tarsus Pharmaceuticals
TARS
75 hedge funds and large institutions have $351M invested in Tarsus Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 28 increasing their positions, 20 reducing their positions, and 7 closing their positions.
9,992% more call options, than puts
Call options by funds: $1.31M | Put options by funds: $13K
40% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 20
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
20% more capital invested
Capital invested by funds: $292M → $351M (+$59.1M)
3% more funds holding
Funds holding: 73 → 75 (+2)
0.97% more ownership
Funds ownership: 75.89% → 76.85% (+0.97%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.44M |
| 2 |
BlackRock
New York
|
+$1.64M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$1.53M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$1.3M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$2.53M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.09M |
| 3 |
IM
Islet Management
New York
|
-$924K |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$797K |
| 5 |
SG Americas Securities
New York
|
-$737K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
76
SG Americas Securities
New York
| – | -$737K | -50,512 | Closed |
|
77
Citadel Advisors
Miami,
Florida
| – | -$331K | -20,873 | Closed |
|
|
CSS
78
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$200K | -13,669 | Closed |
|
|
PWM
79
Prentice Wealth Management
Rochester,
New York
| – | -$4K | -250 | Closed |
|
|
SWM
80
Spire Wealth Management
Mclean,
Virginia
| – | -$1K | -50 | Closed |
|
|
AF
81
Allworth Financial
Folsom,
California
| – | +$191 | +12 | New |
|
|
MPWT
82
MassMutual Private Wealth & Trust
Windsor,
Connecticut
| – | +$365 | +23 | New |
|
TARS Hedge Fund Activity: Q3 2022 in Review
75 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q3 2022, worth a combined $351M — up 20% from $292M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new TARS positions and 7 closed out — a net gain of 2 holders — while 28 added to existing stakes and 20 trimmed.
The largest buyer was Vanguard Group, adding an estimated $4.44M. The largest seller was Assenagon Asset Management, cutting an estimated $2.53M.
- 75 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q3 2022, up from 73 in Q2 2022.
- Funds reported $351M of Tarsus Pharmaceuticals stock for Q3 2022, up 20% quarter-over-quarter.
- 9 funds opened new Tarsus Pharmaceuticals positions in Q3 2022 and 7 closed out, a net change of +2 holders.
- The largest Tarsus Pharmaceuticals buyer in Q3 2022 was Vanguard Group, an estimated $4.44M added.
- The largest Tarsus Pharmaceuticals seller in Q3 2022 was Assenagon Asset Management, an estimated $2.53M sold.
Based on aggregated 13F filings for Q3 2022.